Electrocore, INC

electroCore, Inc. announced the appointment of Joshua Lev and Mike Fox as Co-Chief Executive Officers and directors, effective September 8, 2026, alongside an expansion of the Board and updates to executive compensation and severance policies.

electroCore announced record first quarter 2026 net sales of $9.6 million, a 43% increase year-over-year, and reaffirmed its full-year revenue growth guidance of 30%.

electroCore, Inc. announced record full year 2025 net sales of $32.0 million, a 27% increase, alongside the retirement of CEO Dan Goldberger and new executive appointments.

electroCore, Inc. announced preliminary unaudited financial guidance for full-year 2025, projecting record revenue of $31.8-$32.0 million, representing approximately 26% growth.

electroCore, Inc. announced record third-quarter 2025 financial results with net sales up 33% year-over-year and increased full-year revenue guidance.

electroCore, Inc. issued 360,737 shares of common stock at $5.145 per share to institutional and accredited investors to satisfy outstanding legal fee obligations, receiving no cash proceeds.

electroCore, Inc. reported increased net sales for Q2 2026, but continued operating losses and a significant cash burn have raised substantial doubt about its ability to continue as a going concern.

electroCore reported a 33% increase in Q3 net sales to $8.7 million, driven by prescription and wellness products, but net loss widened to $3.4 million as operating expenses rose.

electroCore, Inc. reported a 20% increase in net sales for Q2 2025, reaching $7.38 million, but net losses widened to $3.67 million, alongside a significant decline in cash and marketable securities.

electroCore's Q1 2025 net sales increased by 23% year-over-year, driven by growth in VA sales and Truvaga product revenue.

electroCore, Inc. reports a 45% increase in net sales for the third quarter of 2024 compared to the same period last year, driven by growth across multiple channels.

electroCore, Inc. saw a significant 73% increase in net sales in Q2 2024 compared to Q2 2023, driven by growth across multiple channels, and has alleviated concerns about its ability to continue as a going concern.

electroCore reports increased 2025 revenue driven by prescription products and general wellness offerings, alongside continued net losses and a CEO retirement, raising going concern doubts.

electroCore's 2024 10-K filing reveals a significant revenue increase driven by key products and strategic partnerships, while also addressing ongoing risks and regulatory challenges.

ElectroCore, Inc.'s annual 10-K filing outlines its share structure, voting rights, anti-takeover provisions, and regulatory compliance, while also highlighting financial risks and future strategies.

Thomas J. Errico, a Director of electroCore, Inc., purchased 5,000 shares of common stock on September 14, 2026 for $9.82 per share.

Michael Fox, See Remarks of electroCore, Inc., purchased 5,000 shares of common stock on September 11, 2026 for $9.80 per share.

Michael Fox, See Remarks of electroCore, Inc., received 5,000 shares of common stock on September 11, 2026.

James Charles Theofilos, a Director of electroCore, Inc., received 11,123 shares of common stock on September 9, 2026.

Joshua S. Lev, CFO and Interim President of electroCore, Inc., sold 20,000 shares of common stock on August 21, 2026.

Thomas J. Errico, a Director of electroCore, Inc., purchased 5,000 shares of common stock on August 13, 2026 for $9.85 per share.

electroCore, Inc. has announced its 2026 Annual Meeting of Stockholders, scheduled for September 8, 2026, to elect directors, ratify auditors, and vote on executive compensation.

electroCore, Inc. has issued its proxy statement for the 2025 Annual Meeting of Stockholders, seeking approval for significant corporate governance changes including board declassification, director elections, auditor ratification, and executive compensation.

electroCore, Inc. will hold its Annual Meeting of Stockholders virtually on September 3, 2024, to elect directors, ratify the selection of auditors, and vote on executive compensation matters.

electroCore is registering the resale of up to 1,924,960 shares of common stock by selling securityholders following recent private placement transactions.

electroCore, Inc. has filed a registration statement for the resale of up to 1,924,960 shares of its common stock by selling securityholders, following recent private placement transactions.

A group of investors, led by Charles and Kathryn Theofilos, has significantly increased their stake in electroCore, Inc. and declared their intent to seek changes in the company's control and corporate governance.

MAZ Partners LP and its affiliates, including Walter and Susan Schenker, have disclosed a 1.8% beneficial ownership stake in electroCore, Inc., indicating they are evaluating potential changes to the company's board of directors or management.

Hilve Holdings Ltd and Mikhail Stiskin have jointly reported beneficial ownership of 517,522 shares, representing 6.4% of electroCore, Inc.'s common stock.

AWM Investment Company, Inc. has increased its beneficial ownership in electroCore, Inc. to 6.0% through warrants, as disclosed in its latest Schedule 13G filing.

Hilve Holdings Ltd and Mikhail Stiskin have disclosed a beneficial ownership of 5.7% in electroCore, Inc., totaling 432,000 shares of common stock.

Charles and Kathryn Theofilos, along with Happy Holstein Management, LLC, have reclassified their significant stake in electroCore, Inc. to passive ownership, filing an amended Schedule 13G and removing James Theofilos as a reporting person.

Tianyi Zhang, a Chinese citizen, has disclosed a 9.90% passive beneficial ownership stake in electroCore, Inc., holding 734,638 shares of common stock.

Charles and Kathryn Theofilos, along with Happy Holstein Management, LLC, have reclassified their beneficial ownership in electroCore, Inc. to a passive investment, filing an amended Schedule 13G and superseding their previous Schedule 13D.